Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML
- Status
- WITHDRAWN
- Phase
- PHASE1
Clinical Trials Related to AML
Related studies linked through entity extraction aliases.
ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation
- Status
- UNKNOWN
- Phase
- NA
Donor-derived CAR-T Cells in the Treatment of AML Patients
- Status
- UNKNOWN
- Phase
- PHASE1
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Flotetuzumab Expanded Access Program
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
- Status
- RECRUITING
- Phase
- PHASE2
NK Cell Therapy Recurrent/Refractory Elderly AML
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Diagnosis and Treatment of Periodontal Disease in Patients With AML
- Status
- WITHDRAWN
- Phase
- NA
Haplo Peripheral Blood Sct In GVHD Prevention
- Status
- COMPLETED
- Phase
- PHASE1
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE1
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
- Status
- TERMINATED
- Phase
- PHASE2
Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
- Status
- RECRUITING
- Phase
- PHASE1
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
- Status
- UNKNOWN
- Phase
- PHASE1
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
- Status
- WITHDRAWN
- Phase
- PHASE1
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML
- Status
- RECRUITING
- Phase
- PHASE2
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
- Status
- COMPLETED
- Phase
- PHASE1